Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency
- PMID: 32531107
- DOI: 10.1111/ajt.16143
Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency
Abstract
Medical-refractory severe alcoholic hepatitis (AH) has a high mortality. The national frequency, longer term outcomes and regional practices of AH liver transplantation (LT) in the United States are not well described, despite the increasing mortality from alcohol-associated liver disease. We analyzed the trends in frequency and outcomes of UNOS data on 39 455 adult patients who underwent LT from 2014 to 2019, including AH LT recipients. LTs for AH increased 5-fold, from 28 in 2014 to 138 in 2019, varying 8-fold between UNOS regions. Three transplant centers accounted for 50%-90% of AH LTs within each region. The number of transplant centers performing AH LTs increased from 14 in 2014 to 47 in 2019. AH patients were younger (mean = 39.4 years), had higher MELD scores (mean = 36.8), and were more often on dialysis (46.0%) and in ICU (38.4%), compared to other indications (all P < .05). One- and 5-year graft survivals for AH LT recipients were 91.7% and 81.9%, respectively. The frequency of AH LT is increasing rapidly, with excellent medium-term outcomes. An impact of AH recurrence on patient or graft survival is not apparent in this national analysis. There are marked geographic variations in practices, highlighting the lack of selection criteria standardization.
Keywords: Organ Procurement and Transplantation Network (OPTN); United Network for Organ Sharing (UNOS); alcoholism and substance abuse; clinical research/practice; liver allograft function/dysfunction; liver disease; liver transplantation/hepatology.
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.
Comment in
-
Alcohol-associated hepatitis and liver transplantation: Mind the (racial, sex, economic, geographic, center, waitlist, and posttransplant outcomes) gap.Am J Transplant. 2021 Mar;21(3):921-922. doi: 10.1111/ajt.16243. Epub 2020 Aug 29. Am J Transplant. 2021. PMID: 32860654 No abstract available.
References
REFERENCES
-
- Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25:108-111.
-
- Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-related liver diseases: 2019 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020.71:306-333.
-
- Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758-2769.
-
- Mathurin P, Mendenhall CL, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36:480-487.
-
- Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353-358.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
